Cybin Hopes to Attach Its Training Program to New AMA Codes

Cybin noted that the new codes create a clearer path for insurance reimbursement.

As the medical community begins to set the stage for standardizing psychedelic treatments, Cybin Inc. (NEO:CYBN) (NYSE:CYBN) has begun development of a streamlined, scalable version of its Embark Training Program.

Cybin originally launched the Embark psychedelic facilitator training program in October 2021, but it is now getting new life following the recent move by the American Medical Association’s to establish codes for treatment.

Last week, Green Market Report wrote about The AMA’s new set of codes for psychedelic medication therapy. This is an important step in securing insurance coverage for these emerging treatments and integrating psychedelic therapies into mainstream medical practices.

The new CPT Category III code, an indicator of a procedure’s medical significance and complexity, mostly pertains to continuous in-person monitoring and intervention during psychedelic medication therapy. These CPT codes, which take effect Jan. 1, 2024, establish a standardized way to identify a procedure and are intended to allow data to be collected to support broader use or a potential U.S. Food and Drug Administration (FDA) approval process.

“As we continue to enhance our Embark facilitator training programs for future pivotal studies of Cybin’s investigational psychedelic-based therapeutics, we are encouraged by the AMA’s new CPT codes, which provide a clearer path for reimbursement and open the door to potentially incorporating psychedelic therapies and support models into the broader healthcare system,” said Doug Drysdale, Chief Executive Officer of Cybin.

Cybin says that the Embark training program allows the company to effectively screen, qualify, and train facilitators on a multi-site, international level, to provide support and in-person monitoring for study participants receiving the company’s investigational therapeutics in larger pivotal trials. Cybin also offers a free online training course called Embark Open Access which could set the stage for expanding access to training resources, and may serve as a bridge for facilitators to be enrolled in future Embark training programs and potentially participate in future Cybin-sponsored clinical trials.

Last month, Cybin released its earnings for the past year with a loss of C$47.5 million. The company has no real revenue at this time and included the training program in its recent MD&A with a list of non-revenue generating programs.

Debra Borchardt

Debra Borchardt is the Co-Founder, and Executive Editor of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Master's degree in Business Journalism from New York University.


Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.